GLP-1 Drugs Shrink Fat but May Sacrifice Muscle — What the Evidence Shows

GLP-1 receptor agonists have transformed obesity and type 2 diabetes management, but their impact on body composition — particularly lean and skeletal muscle mass — remains incompletely characterized. This 2025 narrative review from the National and Kapodistrian University of Athens synthesizes physiological, preclinical, and clinical evidence to address a clinically urgent question: as patients lose large amounts of weight on these drugs, what happens to their muscle?

The review begins with the physiology of three key incretin hormones. GLP-1, secreted by intestinal L-cells, drives insulin secretion, slows gastric emptying, and suppresses appetite via central GLP-1 receptors. GIP, the first identified incretin, modulates lipid storage and vascular health in addition to stimulating insulin. Glucagon promotes hepatic glucose output and energy expenditure but, when chronically elevated (as in obesity and T2D), may drive muscle catabolism. Understanding these distinct roles is essential for predicting how mono-, dual-, and triple-agonist drugs differentially affect tissue.

The authors then profile two critical muscle-related conditions. Sarcopenia — defined by the EWGSOP as concurrent low muscle mass, strength, and physical performance — affects 10–16% of older adults and is strongly linked to T2D and MASLD. Sarcopenic obesity (SO), affecting ~11% of older adults globally and projected to reach 200 million people by 2050, compounds metabolic risk beyond either condition alone. Myosteatosis (intramuscular fat infiltration) is identified as an independent driver of insulin resistance and an early biomarker of metabolic disease, diagnosable via CT imaging.

On the clinical evidence side, large RCTs confirm that GLP-1 RAs such as liraglutide and semaglutide, and dual agonists like tirzepatide, reduce total body weight substantially — with fat mass accounting for 70–80% of losses. However, lean mass losses of 20–30% of total weight reduction are consistently observed in absolute terms across trials. Whether these reductions impair muscle function, accelerate frailty, or simply reflect proportional scaling with total weight loss remains unresolved. Data on triple agonists (GLP-1/GIP/GCG) are emerging but limited. The review notes that preclinical models suggest GLP-1 signaling may have direct anabolic or anti-atrophic effects on muscle, but these have not translated clearly to human functional outcomes.

The authors advocate strongly for adjunctive strategies. Resistance training and adequate dietary protein intake are highlighted as the most evidence-supported interventions to attenuate lean mass loss during pharmacological weight reduction. Emerging anabolic approaches — including myostatin inhibition and ActRII blockade — are flagged as promising but still investigational. Importantly, the review calls for standardized use of DEXA, MRI, and CT in future trials, alongside functional endpoints (grip strength, gait speed, chair-stand tests), to move beyond weight-centric outcomes.